| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Delfini Lisa serves as a Chief Financial Officer at TRVI. Across recent SEC filings that breaks down to 0 buys and 10 sells. Those positions are worth an estimated $33K at current prices.
Historically, Delfini Lisa's trades have earned a middling insider score of 52/100 across 10 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -29.5%.
The biggest single holding is TRVI (~$33K) as Chief Financial Officer. The recent filings there lean toward selling, a net 18,593 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 22, 2024 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 4,350 | $2.64 | $11,484.87 | -7.5% | +7.5% | +127.5% | |
| Oct 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 785 | $2.02 | $1,585.70 | -2.1% | -33.8% | +47.1% | |
| Sep 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 711 | $2.20 | $1,564.20 | -2.0% | -49.1% | +39.4% | |
| Aug 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 682 | $2.36 | $1,609.52 | -2.0% | -43.1% | +20.2% | |
| Jul 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 687 | $2.34 | $1,607.58 | -2.2% | -10.1% | +16.7% | |
| Jun 12, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 610 | $2.64 | $1,610.40 | -2.0% | -11.7% | +1.6% | |
| May 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 562 | $2.89 | $1,624.18 | -2.0% | -23.0% | -9.0% | |
| Apr 11, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 840 | $1.84 | $1,544.76 | -3.1% | +29.0% | +49.2% | |
| Mar 13, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 892 | $1.75 | $1,563.85 | -3.5% | +36.9% | +54.5% | |
| Feb 13, 2023 | TRVI Trevi Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 8,474 | $2.45 | $20,761.30 | -26.6% | +7.8% | -24.9% |